Edwin M Posadas
Overview
Explore the profile of Edwin M Posadas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
101
Citations
2510
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Morgan T, Boorjian S, Buyyounouski M, Chapin B, Chen D, Cheng H, et al.
J Urol
. 2024 Feb;
211(4):526-532.
PMID: 38421252
Purpose: The summary presented herein covers recommendations on salvage therapy for recurrent prostate cancer intended to facilitate care decisions and aid clinicians in caring for patients who have experienced a...
12.
Morgan T, Boorjian S, Buyyounouski M, Chapin B, Chen D, Cheng H, et al.
J Urol
. 2024 Feb;
211(4):518-525.
PMID: 38421243
Purpose: The summary presented herein covers recommendations on salvage therapy for recurrent prostate cancer intended to facilitate care decisions and aid clinicians in caring for patients who have experienced a...
13.
Murata M, Igari F, Urbanowicz R, Mouakkad L, Kim S, Chen Z, et al.
bioRxiv
. 2023 Nov;
PMID: 37961589
Plasma cell-free DNA (cfDNA) is a promising source of gene mutations for cancer detection by liquid biopsy. However, no current tests interrogate chromosomal structural variants (SVs) genome-wide. Here, we report...
14.
Qian C, Yang Q, Rotinen M, Huang R, Kim H, Gallent B, et al.
bioRxiv
. 2023 Oct;
PMID: 37905039
Androgen receptor- (AR-) indifference is a mechanism of resistance to hormonal therapy in prostate cancer (PC). Here we demonstrate that the HOX/CUT transcription factor ONECUT2 (OC2) activates resistance through multiple...
15.
Mrdenovic S, Wang Y, Yin L, Chu G, Ou Y, Lewis M, et al.
BMC Cancer
. 2023 Jun;
23(1):499.
PMID: 37268911
Background: Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer and is notorious for its resistance to both chemotherapy and small-molecule inhibitor targeted therapies. Subcellular...
16.
Wang Z, Kim S, Tu W, Kim J, Xu A, Yang Y, et al.
Cell Metab
. 2023 May;
35(7):1209-1226.e13.
PMID: 37172577
Liver metastasis is a major cause of death in patients with colorectal cancer (CRC). Fatty liver promotes liver metastasis, but the underlying mechanism remains unclear. We demonstrated that hepatocyte-derived extracellular...
17.
Wang J, Sun N, Lee Y, Kim M, Vagner T, Rohena-Rivera K, et al.
Nano Today
. 2023 Jan;
48.
PMID: 36711067
Optimizing outcomes in prostate cancer (PCa) requires precision in characterization of disease status. This effort was directed at developing a PCa extracellular vesicle (EV) Digital Scoring Assay (DSA) for detecting...
18.
Sjostrom M, Zhao S, Levy S, Zhang M, Ning Y, Shrestha R, et al.
Cancer Res
. 2022 Oct;
82(21):3888-3902.
PMID: 36251389
Significance: In prostate cancer, 5-hydroxymethylcytosine delineates oncogene activation and stage-specific cell states and can be analyzed in liquid biopsies to detect cancer phenotypes. See related article by Wu and Attard,...
19.
Smith B, Mishra R, Billet S, Placencio-Hickok V, Kim M, Zhang L, et al.
Mol Ther
. 2022 Sep;
31(1):78-89.
PMID: 36045587
Androgen receptor signaling inhibitors (ARSIs) are standard of care for advanced prostate cancer (PCa) patients. Eventual resistance to ARSIs can include the expression of androgen receptor (AR) splice variant, AR-V7,...
20.
Sun N, Zhang C, Lee Y, Tran B, Wang J, Kim H, et al.
Hepatology
. 2022 Jul;
77(3):774-788.
PMID: 35908246
Background And Aims: The sensitivity of current surveillance methods for detecting early-stage hepatocellular carcinoma (HCC) is suboptimal. Extracellular vesicles (EVs) are promising circulating biomarkers for early cancer detection. In this...